Literature DB >> 6845404

Propranolol, propranolol glucuronide, and naphthoxylactic acid in breast milk and plasma.

M T Smith, I Livingstone, W D Hooper, M J Eadie, E J Triggs.   

Abstract

High-performance liquid chromatographic assays for propranolol and its major metabolites in plasma and breast milk are described. The breast milk/whole plasma ratios of propranolol in three lactating women were in the range of 0.33 to 1.65. The half-life of elimination of propranolol from breast milk was 6.5 +/- 3.4 h (mean +/- SD), which was significantly longer (t = 1.844, df = 4, p less than 0.01) than the half-life of elimination of propranolol from plasma, which was 2.6 +/- 1.2 h (mean +/- SD). The half-life of elimination of the propranolol metabolite naphthoxylactic acid from breast milk was 4.2 +/- 0.9 h (mean +/- SD), which was not significantly different (t = 0.042, df = 4, p greater than 0.05) from the mean half-life of elimination from plasma, which was 4.2 +/- 1.2 h (mean +/- SD). The penetration of propranolol glucuronide into breast milk was slower and to a lesser extent than that of propranolol and naphthoxylactic acid. The maximum dose, calculated from the results presented in this paper, ingested as either propranolol or as propranolol glucuronide in breast milk by the neonate would be less than 0.1% of the maternal dose.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6845404     DOI: 10.1097/00007691-198303000-00008

Source DB:  PubMed          Journal:  Ther Drug Monit        ISSN: 0163-4356            Impact factor:   3.681


  8 in total

1.  Chronic propranolol administration during pregnancy. Maternal pharmacokinetics.

Authors:  M T Smith; I Livingstone; M J Eadie; W D Hooper; E J Triggs
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

2.  Metabolism of propranolol in the human maternal-placental-foetal unit.

Authors:  M T Smith; I Livingstone; M J Eadie; W D Hooper; E J Triggs
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

Review 3.  The pharmacokinetics of antiarrhythmic agents in pregnancy and lactation.

Authors:  G M Mitani; I Steinberg; E J Lien; E C Harrison; U Elkayam
Journal:  Clin Pharmacokinet       Date:  1987-04       Impact factor: 6.447

Review 4.  Drugs in human milk. Clinical pharmacokinetic considerations.

Authors:  H C Atkinson; E J Begg; B A Darlow
Journal:  Clin Pharmacokinet       Date:  1988-04       Impact factor: 6.447

Review 5.  Principles of drug biodisposition in the neonate. A critical evaluation of the pharmacokinetic-pharmacodynamic interface (Part I).

Authors:  J B Besunder; M D Reed; J L Blumer
Journal:  Clin Pharmacokinet       Date:  1988-04       Impact factor: 6.447

6.  Propranolol steady-state pharmacokinetics are unaltered by omeprazole.

Authors:  D Henry; P Brent; I Whyte; G Mihaly; S Devenish-Meares
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

Review 7.  The Risk for Neonatal Hypoglycemia and Bradycardia after Beta-Blocker Use during Pregnancy or Lactation: A Systematic Review and Meta-Analysis.

Authors:  Rosalie de Bruin; Sarah L van Dalen; Shamaya J Franx; Viraraghavan V Ramaswamy; Sinno H P Simons; Robert B Flint; Gerbrich E van den Bosch
Journal:  Int J Environ Res Public Health       Date:  2022-08-04       Impact factor: 4.614

8.  Risk for neonatal hypoglycaemia and bradycardia after beta-blocker use during pregnancy or lactation: a systematic review and meta-analysis protocol.

Authors:  Rosalie de Bruin; Sarah L van Dalen; Shamaya J Franx; Sinno Hp Simons; Robert B Flint; Gerbrich E van den Bosch
Journal:  BMJ Open       Date:  2022-08-25       Impact factor: 3.006

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.